CSL Limited (FRA:CSJA)

Market Cap	51.49B -36.0%
Revenue (ttm)	13.25B +5.1%
Net Income	2.56B +13.6%
EPS	5.25 +13.2%
Shares Out	n/a
PE Ratio	20.14
Forward PE	18.02
Dividend	1.20 (2.33%)
Ex-Dividend Date	Sep 10, 2025

Volume	n/a
Average Volume	n/a
Open	51.50
Previous Close	52.00
Day's Range	51.50 - 51.50
52-Week Range	47.00 - 83.50
Beta	n/a
RSI	65.97
Earnings Date	Feb 9, 2026

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1916
• Employees: 29,904
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CSJA

Financial Performance

In fiscal year 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.

Financial numbers in USD